{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:24:05Z","timestamp":1779135845214,"version":"3.51.4"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Malignant pleural effusion (MPE) is a common complication of lung adenocarcinoma (LADC) which is associated with a dismal prognosis. We investigated the prognostic role of PD-L1 and other immunomodulators expression in the immune compartment of MPE immune composition. MPE cytologic cell blocks of 83 LADC patients were analysed for the mRNA expression of 770 cancer-immune genes by the NanoString nCounter platform. The expression of relevant immune cell lineage markers was validated by immunohistochemistry (IHC) using quantitative pathology. The mRNA immune profiling identified four MPE patient clusters (C). C1\/2 (adaptive+, hot) showed better overall survival (OS) than C3\/4 (adaptive-, cold). Additionally, cold immunity profiles (adaptive-), C4 (innate+) were associated with worse OS than C3 (innate-). High PD-L1 expression was linked to the regulation of T cell activation and interferon signalling pathways. Genes of pattern recognition receptor and type I interferon signalling pathways were specifically upregulated in the long-survival (\u226590 days) patient group. Moreover, immunomodulators were co-activated and highly expressed in hot adaptive immunity patient clusters, whereas <jats:italic>CD274<\/jats:italic> (PD-L1), <jats:italic>TNFRSF9<\/jats:italic> (4-1BB), <jats:italic>VEGFA<\/jats:italic> (VEGF-A) and <jats:italic>CD276<\/jats:italic> (B7-H3) were upregulated in the groups referred as cold. The patient cluster, age and PD-L1 expression were independent prognosticators for LADC MPE patients (p-value &amp;lt; 0.05). Our study sheds light on the variances of immune contexture regarding different PD-L1 expression and survival conditions. It revealed four distinct prognostic patient clusters with specific immune cell components and immunomodulator expression profiles, which, collectively, is supportive for future therapeutic and prognosis for cancer management.<\/jats:p>","DOI":"10.3389\/fonc.2022.1031094","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T07:19:24Z","timestamp":1664867964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival"],"prefix":"10.3389","volume":"12","author":[{"given":"Cheng-Guang","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Soltermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2007.09.014","article-title":"Prognostic significance of pleural fluid data in patients with malignant effusion","volume":"19","author":"Bielsa","year":"2008","journal-title":"Eur J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994","article-title":"Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010","volume":"65","author":"Roberts","year":"2010","journal-title":"Thorax"},{"key":"B3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-019-0590-4","article-title":"Treatment of malignant pleural effusions: The case for localized immunotherapy","volume":"7","author":"Donnenberg","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20280","article-title":"Tumor microenvironment: What can effusions teach us","volume":"33","author":"Kassis","year":"2005","journal-title":"Diagn Cytopathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.imbio.2016.10.017","article-title":"Regulatory T cells in malignant pleural effusions subsequent to lung carcinoma and their impact on the course of the disease","volume":"222","author":"Budna","year":"2017","journal-title":"Immunobiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3547","article-title":"Cd163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3079-x","article-title":"Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer","volume":"36","author":"Xu","year":"2015","journal-title":"Tumour Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.04.009","article-title":"Upregulation of soluble B7-H3 in nsclc-derived malignant pleural effusion: A potential diagnostic biomarker correlated with nsclc staging","volume":"457","author":"Chen","year":"2016","journal-title":"Clin Chim Acta"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1152-8","article-title":"Cell origins and significance of il-17 in malignant pleural effusion","volume":"16","author":"Gong","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121953","article-title":"Prognostic immune cell profiling of malignant pleural effusion patients by computerized immunohistochemical and transcriptional analysis","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12967-020-02331-x","article-title":"In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening","volume":"18","author":"Wu","year":"2020","journal-title":"J Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0342","article-title":"Immune cell gene signatures for profiling the microenvironment of solid tumors","volume":"6","author":"Nirmal","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy399","article-title":"Immunological differences between primary and metastatic breast cancer","volume":"29","author":"Szekely","year":"2018","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3509","article-title":"A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations","volume":"24","author":"Tamborero","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2140","article-title":"Association between genomic metrics and immune infiltration in triple-negative breast cancer","volume":"3","author":"Karn","year":"2017","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-Pd-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000408","article-title":"Development of a companion diagnostic pd-L1 immunohistochemistry assay for pembrolizumab therapy in non-Small-Cell lung cancer","volume":"24","author":"Roach","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (Pd-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and pd-L1 expression in metastasized malignant melanoma","volume":"117","author":"Gadiot","year":"2011","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of pd-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of Tim-3, lag-3, pd-1 and pd-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of alcam (Cd166) and pd-L1 (Cd274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.034","article-title":"Pd-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion","volume":"13","author":"Tseng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/2043-9113-1-25","article-title":"Automated Ercc1 immunochemistry on hybrid Cytology\/Tissue microarray of malignant effusions: Evaluation of antibodies 8f1 and d-10","volume":"1","author":"Soltermann","year":"2011","journal-title":"J Clin Bioinforma"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for rna-seq data with Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp101","article-title":"Cluego: A cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"Qupath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-Pd-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: From basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: Neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0544-x","article-title":"Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification","volume":"7","author":"Monette","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253654","article-title":"Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis","volume":"6","author":"Hendrickx","year":"2017","journal-title":"Oncoimmunology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of ctla-4 and pd-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (Cd276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of Cd276\/B7-H3-Positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-019-09084-w","article-title":"B7-H3 modulates endothelial cell angiogenesis through the vegf cytokine","volume":"67","author":"Lai","year":"2019","journal-title":"Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer Via dsrna including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2326-0","article-title":"Immune cell landscape in therapy-naive squamous cell and adenocarcinomas of the lung","volume":"472","author":"Brcic","year":"2018","journal-title":"Virchows Arch"},{"key":"B49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.trsl.2017.08.004","article-title":"The anticancer functions of rig-I-Like receptors, rig-I and Mda5, and their applications in cancer therapy","volume":"190","author":"Wu","year":"2017","journal-title":"Transl Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-Alpha\/Beta signalling to P53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.10.026","article-title":"High Trem2 expression correlates with poor prognosis in gastric cancer","volume":"72","author":"Zhang","year":"2018","journal-title":"Hum Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8813","article-title":"Trem-2 serves as a negative immune regulator through syk pathway in an il-10 dependent manner in lung cancer","volume":"7","author":"Yao","year":"2016","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1031094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T07:19:28Z","timestamp":1664867968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1031094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":52,"alternative-id":["10.3389\/fonc.2022.1031094"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1031094","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"article-number":"1031094"}}